Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate in two investor conferences in September: the Annual Barrington Research Fall Investment Conference and the Rodman & Renshaw Annual Global Investment Conference.
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will be available for one-on-one meetings with the investment community on September 3, 2014 at the Annual Barrington Research Fall Investment Conference taking place September 3 - 4, 2014 at the Four Seasons Hotel, in Chicago.
Mr. Berlin will also present a corporate overview at the Rodman & Renshaw Annual Global Investment Conference being held from September 8 - 10, 2014 at the New York Palace Hotel. Mr. Berlin's presentation is scheduled for September 10, 2014 at 3:20 p.m. The presentation will be webcast live and archived online at the Investors section of the Company's website at www.rosettagenomics.com.
About Rosetta Genomics
Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics. Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. For more information please visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test, the Cancer Origin Test improving the ability of physicians to accurately diagnose CUP, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's cancer testing services, particularly the Cancer Origin Test, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2013 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
President & CEO
Anne Marie Fields
SOURCE: Rosetta Genomics, Ltd.